Monday - July 14, 2025

LOGIN  |  REGISTER
Assertio
Viking Therapeutics

Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference

April 16, 2025 | Last Trade: US$1.80 0.23 14.59

BOTHELL, Wash., April 16, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that Sam Lee, President and co-CEO, will present a Company overview at the Life Science Innovation Northwest (LSINW) 2025 Conference on Wednesday, April 23, 2025 at 3:00 p.m. Pacific time. The conference is being held April 23-24 at the Seattle Convention Center.

About Life Science Innovation Northwest

Life Science Innovation Northwest (LSINW) is the Pacific Northwest’s largest annual life science conference. This event brings together investors, public and private life science organizations, research institutions, scientists, entrepreneurs, and the global health community to discuss and feature some of the most compelling life science breakthroughs of our time. Bringing together over 700 attendees, LSINW features 80+ company and research institution presentations, keynote addresses from industry leaders, engaging panel discussions on emerging trends, a dynamic startup fast pitch showdown, insightful poster presentations, and more - making it the must-attend event for the PNW’s life science community. More information is available here.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Contact:
Alliance Advisors IR
Jody Cain
310-691-7100
jcain@allianceadvisors.com

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page